Brokerages Expect Supernus Pharmaceuticals Inc (NASDAQ:SUPN) Will Post Quarterly Sales of $108.92 Million

Equities research analysts predict that Supernus Pharmaceuticals Inc (NASDAQ:SUPN) will report sales of $108.92 million for the current quarter, Zacks reports. Four analysts have provided estimates for Supernus Pharmaceuticals’ earnings, with the highest sales estimate coming in at $112.26 million and the lowest estimate coming in at $107.10 million. Supernus Pharmaceuticals reported sales of $99.54 million during the same quarter last year, which indicates a positive year-over-year growth rate of 9.4%. The firm is expected to announce its next quarterly earnings report on Tuesday, August 6th.

On average, analysts expect that Supernus Pharmaceuticals will report full year sales of $439.18 million for the current fiscal year, with estimates ranging from $428.00 million to $448.46 million. For the next year, analysts expect that the company will report sales of $516.10 million, with estimates ranging from $505.79 million to $526.01 million. Zacks’ sales calculations are an average based on a survey of research firms that follow Supernus Pharmaceuticals.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its earnings results on Tuesday, May 7th. The specialty pharmaceutical company reported $0.34 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.44 by ($0.10). Supernus Pharmaceuticals had a return on equity of 23.60% and a net margin of 25.49%. The firm had revenue of $85.50 million during the quarter, compared to the consensus estimate of $102.26 million. During the same quarter in the prior year, the business earned $0.49 earnings per share. Supernus Pharmaceuticals’s revenue for the quarter was down 5.4% on a year-over-year basis.

SUPN has been the subject of a number of analyst reports. Zacks Investment Research raised Supernus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $44.00 price target for the company in a research report on Wednesday, March 13th. BidaskClub lowered Supernus Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Wednesday, March 27th. Mizuho reissued a “buy” rating and issued a $63.00 price target on shares of Supernus Pharmaceuticals in a research report on Thursday, March 28th. Finally, Cantor Fitzgerald set a $60.00 price target on Supernus Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, May 8th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $55.57.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SUPN. Financial Gravity Wealth Inc. purchased a new stake in shares of Supernus Pharmaceuticals during the 1st quarter valued at $44,000. Advisor Group Inc. increased its holdings in Supernus Pharmaceuticals by 17.2% in the 4th quarter. Advisor Group Inc. now owns 2,082 shares of the specialty pharmaceutical company’s stock worth $69,000 after acquiring an additional 306 shares during the last quarter. Bremer Bank National Association purchased a new stake in Supernus Pharmaceuticals in the 1st quarter worth about $94,000. Huntington National Bank increased its holdings in Supernus Pharmaceuticals by 881.4% in the 1st quarter. Huntington National Bank now owns 4,485 shares of the specialty pharmaceutical company’s stock worth $157,000 after acquiring an additional 4,028 shares during the last quarter. Finally, Adams Diversified Equity Fund Inc. purchased a new stake in Supernus Pharmaceuticals in the 1st quarter worth about $200,000. 99.29% of the stock is owned by institutional investors and hedge funds.

Shares of SUPN traded up $0.04 during trading hours on Wednesday, reaching $32.25. The stock had a trading volume of 8,864 shares, compared to its average volume of 556,461. Supernus Pharmaceuticals has a 12 month low of $29.60 and a 12 month high of $56.40. The stock’s 50-day moving average is $31.76. The company has a debt-to-equity ratio of 0.75, a current ratio of 2.77 and a quick ratio of 2.59. The firm has a market cap of $1.69 billion, a P/E ratio of 15.78, a price-to-earnings-growth ratio of 1.10 and a beta of 1.61.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy and migraine.

Recommended Story: What moving averages are used to define a golden cross?

Get a free copy of the Zacks research report on Supernus Pharmaceuticals (SUPN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.